- Conditions
- Recurrent Renal Cell Carcinoma, Renal Cell Carcinoma
- Interventions
- Sulfur Hexafluoride Lipid Microspheres, Contrast-Enhanced Ultrasound, Computed Tomography, Magnetic Resonance Imaging, Electronic Health Record Review
- Drug · Procedure · Other
- Lead sponsor
- john eisenbrey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1489–1512
of 12,241
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Motor Coordination or Function; Developmental Disorder
- Interventions
- OT-SI
- Other
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 59 Months to 107 Months
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Melanoma Stage IIIB, Melanoma Stage IIIC, Melanoma Stage IIID
- Interventions
- Daromun, Surgery, Adjuvant therapy
- Drug · Procedure
- Lead sponsor
- Philogen S.p.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2031
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • La Jolla, California • Orange, California + 16 more
- Conditions
- Clostridium Difficile Infection Recurrence
- Interventions
- RBX2660
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 12
- States / cities
- North Little Rock, Arkansas • Camarillo, California • Hamden, Connecticut + 9 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- liraglutide, placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 279 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 53
- States / cities
- Concord, California • La Jolla, California • Los Angeles, California + 47 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI, FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS, Placebo DISKUS, Placebo NDPI
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 15
- States / cities
- Tucson, Arizona • Newport Beach, California • Riverside, California + 12 more
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- decitabine
- Drug
- Lead sponsor
- California Cancer Consortium
- Network
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 4
- States / cities
- Duarte, California • Los Angeles, California • Sacramento, California
- Conditions
- Erectile Dysfunction
- Interventions
- Sildenafil Oral Film 25 mg, 50 mg, 75 mg or 100 mg, Placebo
- Drug
- Lead sponsor
- IBSA Institut Biochimique SA
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 488 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 18
- States / cities
- Foley, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 14 more
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Blood sampling
- Other
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Rockland, Massachusetts
- Conditions
- Multiple Myeloma
- Interventions
- Elotuzumab
- Drug
- Lead sponsor
- Sundar Jagannath
- Other
- Eligibility
- 18 Years and older
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pachyonychia Congenita
- Interventions
- PTX-022
- Drug
- Lead sponsor
- Palvella Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Palo Alto, California • Fridley, Minnesota + 1 more
- Conditions
- Anemia
- Interventions
- Ferric Carboxymaltose, Standard Medical Care (SMC)
- Drug
- Lead sponsor
- American Regent, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 513 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Norristown, Pennsylvania
- Conditions
- Multiple Myeloma
- Interventions
- Pasireotide, Everolimus
- Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Multiple Myeloma
- Interventions
- Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 5
- States / cities
- Tucson, Arizona • Fort Myers, Florida • Boston, Massachusetts + 2 more
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- CC100, Placebos
- Drug
- Lead sponsor
- Chemigen, LLC
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Multiple Myeloma
- Interventions
- Elranatamab, Daratumumab, Lenalidomide, Dexamethasone, Bortezomib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,060 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2033
- U.S. locations
- 34
- States / cities
- Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 21 more
- Conditions
- Congenital Bleeding Disorder, Haemophilia A
- Interventions
- turoctocog alfa pegol
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 5
- States / cities
- Iowa City, Iowa • Lexington, Kentucky • Baltimore, Maryland + 2 more
- Conditions
- Caregiver Distress, Emotional Distress, Caregivers, Resilience, Coma, Brain Injury
- Interventions
- Coma Family Program 1, Coma Family Program 2
- Behavioral
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more
- Conditions
- Prader-Willi Syndrome
- Interventions
- Oxytocin, Placebo
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 1 Week to 6 Months
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Multiple Myeloma
- Interventions
- Acupuncture, Sham acupuncture
- Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Long QT Syndrome
- Interventions
- LQT-1213, Placebo
- Drug · Other
- Lead sponsor
- Thryv Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Mucositis, Multiple Myeloma
- Interventions
- Palifermin, melphalan, questionnaire administration, autologous peripheral blood stem cell transplantation, quality-of-life assessment
- Biological · Drug · Other + 1 more
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Pulmonary Embolism, Thrombotic Disease
- Interventions
- DS-1040b, Placebo, Enoxaparin
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 15
- States / cities
- Mobile, Alabama • Beverly Hills, California • San Diego, California + 12 more
- Conditions
- Kidney Disease, Chronic
- Interventions
- BI 690517, Placebo to BI 690517, Empagliflozin, Placebo to empagliflozin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 714 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 41
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Canyon Country, California + 34 more